Determining Efficacy
MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients
Genomics Data 2016 June 20 [Link] Lin RC, Kirschner MB, Cheng YY, van Zandwijk N, Reid G Abstract Malignant pleural mesothelioma (MPM) is a tumor originating in the mesothelium, the membrane lining the thoracic cavities, and is induced by exposure to asbestos. Australia suffers one of the world’s highest rates of MPM and the incidence…
Read MoreProtocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters
BMJ Open 2016 July 5 [Epub ahead of print] [Link] Azzopardi M, Thomas R, Muruganandan S, Lam DC, Garske LA, Kwan BC, Rashid Ali MR, Nguyen PT, Yap E, Horwood FC, Ritchie AJ, Bint M, Tobin CL, Shrestha R, Piccolo F, De Chaneet CC, Creaney J, Newton RU, Hendrie D, Murray K, Read CA, Feller-Kopman…
Read MoreP2X7 targeting inhibits growth of human mesothelioma
Oncotarget 2016 July 6 [Epub ahead of print] [Link] Amoroso F, Salaro E, Falzoni S, Chiozzi P, Giuliani AL, Cavallesco G, Maniscalco P, Puozzo A, Bononi I, Martini F, Tognon M, Di Virgilio F Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor refractory to anti-blastic therapy. MPM cells show several genetic and biochemical defects,…
Read MoreUsefulness of Aquaporin 1 as a Prognostic Marker in a Prospective Cohort of Malignant Mesotheliomas
International Journal of Molecular Sciences 2016 June 30 [Link] Driml J, Pulford E, Moffat D, Karapetis C, Kao S, Griggs K, Henderson DW, Klebe S Abstract (1) Background: Malignant mesothelioma (MM) is an aggressive tumour of the serosal membranes, associated with exposure to asbestos. Survival is generally poor, but prognostication for individual patients is difficult.…
Read MoreNanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma
Biomaterials 2016 June 22 [Epub ahead of print] [Link] Liu R, Colby AH, Gilmore D, Schulz M, Zeng J, Padera RF, Shirihai O, Grinstaff MW, Colson YL Abstract The treatment outcomes for malignant peritoneal mesothelioma are poor and associated with high co-morbidities due to suboptimal drug delivery. Thus, there is an unmet need for new…
Read MorePhase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma
Journal of Clinical Oncology: Official journal of the American Society of Clinical Oncology 2016 June 20 [Epub ahead of print] [Link] Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, Woo KM, Shen R, Ginsberg MS, Yorke ED, Rice DC, Tsao AS, Rosenzweig KE, Rusch VW, Krug LM. Abstract PURPOSE: We conducted…
Read MoreAntitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model
Cancer Science 2016 June 13 [Epub ahead of print] [Link] Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y. Abstract Podoplanin (Aggrus) is highly expressed in several types of cancers, including malignant pleural mesothelioma (MPM). Previously,…
Read MoreEffect of renal function on pemetrexed-induced haematotoxicity
Cancer, chemotherapy, and pharmacology [Epub ahead of print] [ Link] Ando Y, Hayashi T, Ujita M, Murai S, Ohta H, Ito K, Yamaguchi T, Funatsu M, Ikeda Y, Imaizumi K, Kawada K, Yasuda K, Yamada S. Abstract PURPOSE: Pemetrexed (PEM) is an anticancer agent used for the treatment of non-small cell lung cancer, malignant pleural…
Read MoreInhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230
Ontarget 2016 May 20 [Epub ahead of print] [Link] Blackwell C, Sherk C, Fricko M, Ganji G, Barnette M, Hoang B, Tunstead J, Skedzielewski T, Alsaid H, Jucker BM, Minthorn E, Kumar R, DeYoung MP. Abstract Fibroblast growth factor (FGF) ligand-dependent signaling has a fundamental role in cancer development and tumor maintenance. GSK3052230 (also known…
Read MorePharmacokinetics and the effect of heat on intraperitoneal pemetrexed using a murine model
Surgical Oncology 2016 May 20 [Epub ahead of print] [Link] Badrudin D, Perrault-Mercier C, Bouchard-Fortier A, Hubert J, Leblond FA, Sideris L, Dubé P. Abstract BACKGROUND: Pemetrexed is a systemic chemotherapeutic agent used in the treatment of malignant mesothelioma. This drug represents a potentially promising intraperitoneal (IP) agent to use for hyperthermic intraperitoneal chemotherapy (HIPEC)…
Read More